Potent and selective small molecule inhibitors of DOT1L have been developed and tested in preclinical and early-phase clinical trials and showed good tolerability but rather modest efficacy in patients with MLL-rearranged leukemia [24–26]. The gene discussed is KMT2A; the disease is leukemia.